Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets

Rhea-AI Summary

Nektar Therapeutics (Nasdaq: NKTR) will announce financial results for the second quarter ended June 30, 2026 on Thursday, August 13, 2026, after the close of U.S. financial markets. CEO Howard Robin will host a results conference call at 5:00 p.m. ET / 2:00 p.m. PT, accessible via live audio webcast and phone for pre-registered participants.

The webcast will be available on Nektar’s website and offered as a replay through September 13, 2026. Nektar is a clinical-stage biotech focused on autoimmune and chronic inflammatory diseases, led by its T-reg–stimulating candidate rezpegaldesleukin (REZPEG, NKTR-358) and additional preclinical programs.

Market Context

Historical earnings-date reactions included news_id 1047107 at -0.73% and news_id 1019891 at 4.67%. ...

Analysis

Historical earnings-date reactions included news_id 1047107 at -0.73% and news_id 1019891 at 4.67%. The announcement provides scheduling information; recent insider activity was classified as Net Selling.

Key Figures

Reporting period: Second quarter ended June 30, 2026 Results announcement: August 13, 2026 Conference call: 5:00 p.m. Eastern Time +3 more

6 metrics

Reporting period Second quarter ended June 30, 2026 Nektar financial results

Results announcement August 13, 2026 After close of U.S.-based financial markets

Conference call 5:00 p.m. Eastern Time Management review of second-quarter results

Conference call 2:00 p.m. Pacific Time Management review of second-quarter results

Webcast replay September 13, 2026 Replay availability through this date

Clinical trial phase Phase 2 NKTR-358 evaluation in Type 1 diabetes mellitus

Previous Earnings date Reports

2 past events · Latest: Apr 28 (Neutral)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 28	Q1 earnings date	Neutral	-0.7%	Scheduled first-quarter results announcement and conference call after the market close
Feb 26	FY2025 earnings date	Neutral	+4.7%	Scheduled fourth-quarter and year-end results announcement after the market close

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Tag-specific earnings-date announcements produced mixed 24-hour reactions: one was -0.73% and another was +4.67%.

Key Terms

regulatory t cell, registrational program, tnfr2, phase 2 clinical trial

4 terms

regulatory t cell medical

"a novel, first-in-class regulatory T cell stimulator"

Regulatory T cells are a type of immune cell that act like peacekeepers, calming other immune cells to prevent excessive or misdirected attacks on the body. For investors, they matter because therapies that boost or block these cells can treat autoimmune diseases, transplant rejection, or cancer, making them a focal point for drug development and a potential driver of company value if therapies prove safe and effective.

registrational program regulatory

"being evaluated in a registrational program in atopic dermatitis"

A registrational program is the set of late-stage clinical studies and regulatory steps designed to show that a drug or medical product is safe and effective enough to win formal approval from health authorities. Think of it like the final licensing exams a product must pass before it can be sold widely; investors watch these programs closely because successful results clear the way to market access, revenue potential, and lower regulatory risk, while failures can halt commercial plans.

tnfr2 medical

"preclinical bivalent tumor necrosis factor receptor type II (TNFR2)"

TNFR2 is a protein on the surface of certain immune and other cells that acts like a lock for the signaling molecule TNF; when engaged it changes cell behavior such as promoting cell survival or regulating immune responses. Investors watch TNFR2 because drugs that block or activate it are being developed for cancer and autoimmune diseases, so clinical trial results or biomarker data tied to TNFR2 can materially affect a therapy’s commercial prospects and a company’s valuation.

phase 2 clinical trial medical

"being evaluated in one Phase 2 clinical trial"

A phase 2 clinical trial is a research study that tests a new medical treatment or drug to see if it is effective and safe for a specific condition. It involves a larger group of people than earlier trials and helps determine whether the treatment should move forward to more extensive testing. For investors, successful phase 2 results can signal potential for future approval and commercial success, while setbacks may indicate challenges ahead.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, July 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2026 on Thursday, August 13, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The web broadcast of the conference call will be available for replay through September 13, 2026.

To access the conference call, please pre-register here.  All registrants will receive dial-in information and a PIN allowing them to access the live call.

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in a registrational program in atopic dermatitis, being planned for a registrational program in alopecia areata, and being evaluated in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422.

Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.

Contacts

For Investors:

Vivian Wu
628-895-0661
VWu@nektar.com 

Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com 

For Media:

Susan Roberts
LifeSci Communications
202-779-0929
sroberts@lifescicomms.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-to-announce-financial-results-for-the-second-quarter-on-thursday-august-13-2026-after-close-of-us-based-financial-markets-302837015.html

SOURCE Nektar Therapeutics

FAQ

When will Nektar Therapeutics (NASDAQ: NKTR) report its Q2 2026 financial results?

Nektar Therapeutics will report its Q2 2026 financial results on Thursday, August 13, 2026, after U.S. markets close. According to Nektar, the release covers the quarter ended June 30, 2026 and will be followed by a same-day conference call with management.

What time is Nektar Therapeutics’ Q2 2026 earnings conference call for NKTR shareholders?

The Nektar Q2 2026 earnings conference call starts at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time. According to Nektar, CEO Howard Robin will review the quarterly results, and investors can join via pre-registered phone access or a live audio-only webcast.

How can investors access the Nektar Therapeutics (NKTR) Q2 2026 earnings webcast and replay?

Investors can access the Nektar Q2 2026 webcast through links on the Home and Investors sections of the company website. According to Nektar, the audio webcast replay will remain available online through September 13, 2026 for those unable to join live.

Do investors need to pre-register for Nektar Therapeutics’ Q2 2026 earnings call for NKTR stock?

Yes, investors must pre-register via the provided registration link to join the live call. According to Nektar, all registrants receive dial-in details and a unique PIN, which they must use to access the Q2 2026 earnings conference call.

What is Nektar Therapeutics’ main clinical focus and lead drug candidate in 2026 (NKTR)?

Nektar Therapeutics focuses on autoimmune and chronic inflammatory diseases as a clinical-stage biotech company. According to Nektar, its lead candidate is rezpegaldesleukin (REZPEG, NKTR-358), a regulatory T cell stimulator in registrational development for atopic dermatitis and other indications.

Which pipeline programs besides REZPEG does Nektar Therapeutics (NKTR) highlight in 2026?

Nektar highlights preclinical bivalent TNFR2 antibody and bispecific programs NKTR-0165 and NKTR-0166, plus modified CSF protein NKTR-422. According to Nektar, these programs complement REZPEG and target immunological pathways relevant to autoimmune and inflammatory conditions and oncology.